| Ocrelizumab's Place in the Therapeutic Landscape at its 2019 Launch in France |
|
Grégoire Mercier1,2, David Pau3, Guillaume Bourel3, Manon Belhassen4, Floriane Deygas4, Clarisse Marchal4, Sophie Larrieu5, Alexandre Civet3, Xavier Moisset6 |
1Data-Science Unit, Data-Science Unit, Montpellier University Hospital, Montpellier, France
2UMR UA11 IDESP CNRS, University of Montpellier, Montpellier, France
3Roche SAS, Boulogne Billancourt, France
4PELyon, Lyon, France
5Horiana, Bordeaux, France
6Neuro-Dol, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France |
Correspondence:
Manon Belhassen, Tel: +33-481-099-607,
Email: manon.belhassen@pelyon.fr
|
|
Received: 4 February 2025 • Revised: 18 April 2025 • Accepted: 13 June 2025 |
| Abstract |
Background
The treatment landscape for multiple sclerosis (MS) includes a range of disease-modifying therapies (DMTs), from moderate- to high-efficacy agents. Understanding prescribing patterns following the launch of new treatments such as ocrelizumab is essential to assess real-world clinical practices.
Methods
This retrospective cohort study used data from the French National Health Data System between 2019 and 2020. It included 18,912 patients with MS who initiated a DMT during the study period. Patients were categorized according to the initial DMT: moderate-efficacy, or high-efficacy.
Results
Among included patients, 54.5% initiated a moderate-efficacy DMT, 29.5% started ocrelizumab, and 16.0% received a high-efficacy DMT. Most ocrelizumab users (81.2%) were previously treated (non-naïve), compared to 57.6% among moderate-efficacy DMT users and 24.8% among high-efficacy DMT users. Psychiatric and neurological comorbidities were common across all groups (22% overall), with depression reported in 15% of patients.
Conclusion
The strategy of initial high-efficacy treatment was rarely observed in practice during the first year of launch of ocrelizumab in France. Instead, ocrelizumab was predominantly prescribed to previously treated patients who were switching therapies. |
| Key Words:
Multiple sclerosis, Ocrelizumab, Database |
|
PDF Links
Full text via DOI
Download Citation
